Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded?
- 1 February 1989
- journal article
- abstracts
- Published by Wolters Kluwer Health in Circulation
- Vol. 79 (2), 441-444
- https://doi.org/10.1161/01.cir.79.2.441
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarctionThe American Journal of Cardiology, 1988
- Effect of Captopril on Progressive Ventricular Dilatation after Anterior Myocardial InfarctionNew England Journal of Medicine, 1988
- Ventricular Fibrillation Complicating Myocardial InfarctionNew England Journal of Medicine, 1988
- A Randomized Trial of Intravenous Tissue Plasminogen Activator for Acute Myocardial Infarction with Subsequent Randomization to Elective Coronary AngioplastyNew England Journal of Medicine, 1987
- Effect of Intravenous Streptokinase on Left Ventricular Function and Early Survival after Acute Myocardial InfarctionNew England Journal of Medicine, 1987
- Differential effects of reperfusion on incidence of ventricular arrhythmias and recovery of ventricular function at 4 days following coronary occlusionAmerican Heart Journal, 1987
- The Western Washington Randomized Trial of Intracoronary Streptokinase in Acute Myocardial InfarctionNew England Journal of Medicine, 1985
- Western Washington Randomized Trial of Intracoronary Streptokinase in Acute Myocardial InfarctionNew England Journal of Medicine, 1983
- Risk Stratification and Survival after Myocardial InfarctionNew England Journal of Medicine, 1983
- Effects of spontaneous and streptokinase-induced recanalization on left ventricular function after myocardial infarction.Circulation, 1983